Publication details

Úbytek kostní hmoty u androgen deprivační terapie: naléhavý problém pacientů s karcinomem prostaty – naše zkušenosti

Title in English Bone loss of androgen deprivation therapy: an urgent problem in patients with prostate cancer - our experience
Authors

PACÍK Dalibor VÍT Vítězslav KATOLICKÁ Jana JARKOVSKÝ Jiří

Year of publication 2011
Type Article in Periodical
Magazine / Source Urologické listy
MU Faculty or unit

Faculty of Medicine

Citation
Field Other medical specializations
Keywords androgen deprivation therapy; BMD RANKL; denosumab; prostate cancer; pathological fractures
Description Androgen deprivation therapy ADT today plays a vital role in treating patients with locally advanced or metastatic prostate cancer. Bone loss due to ADT leads to increased morbidity and mortality and increased costs. In a group of 104 patients, we investigated the incidence of osteopenia and osteoporosis by measuring bone mineral density. The article offers the results of our investigation and discusses new treatment options CTIBL by a fully human monoclonal antibody denosumab

You are running an old browser version. We recommend updating your browser to its latest version.

More info